SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurobiological Tech (NTII)
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
1494 40 0 NTII
Emcee:  Miles Rhyne Hoffman, CFA Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
744 Clinically available NMDA antagonist, memantine, attenuates tolerance to analgeDr. John M. de Castro-1/5/2000
743 Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especiDr. John M. de Castro-1/5/2000
742 John <<NTII Director makes an open market purchase. 12/99 NTII DIR ELIOTJohn McCarthy-12/28/1999
741 NTII Director makes an open market purchase. 12/99 NTII DIR ELIOT THEODORE L Dr. John M. de Castro-12/28/1999
740 John - Thank you for the follow-up. You *never* know with trials, but my dumbJohn McCarthy-12/23/1999
739 Neuropathic pain clinical results will be out mid to late January. NTII had ledDr. John M. de Castro-12/23/1999
738 Library for NTII Lurkers ........... The *stuff* below will hopefully quickly John McCarthy-12/18/1999
737 was worse then that earlier in weekceleryroot.com-12/17/1999
736 Yahoo! shows the stock down to 2 3/4, but the spread is 2 3/4 -- 3 7/16! MarcJMarcus-12/17/1999
735 John - if there is a P3 .... when would you expect it to start and end? I *thJohn McCarthy-12/17/1999
734 Very positive handwriting on the wall, eerrr, chart. NTII was scheduled to breDr. John M. de Castro-12/14/1999
733 Marc, the first abstract that I posted has to do with memantine's effectiveDr. John M. de Castro-12/3/1999
732 John, what should be NTII's strategy to benefit from these additional possiJMarcus-12/3/1999
731 Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitiveDr. John M. de Castro-12/3/1999
730 Protective Effects of Memantine Against Ischemia-Reperfusion Injury in SpontaneDr. John M. de Castro-12/3/1999
729 Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blinDr. John M. de Castro-12/3/1999
728 Xerecept data in 40 subjects, if consistent with the previous 17 subjects (I amCacaito-11/25/1999
727 Steady hands appear to be in control. I'm amazed that NTII has held its gaiDr. John M. de Castro-11/24/1999
726 Speculations: NTII should pr news about Xerecept data first (if good in the phaCacaito-11/21/1999
725 Rock gets in deeper freeedgar.com Regards John de CDr. John M. de Castro-11/19/1999
724 Hi Marc, No way. The current accumulation pattern is by your second tier grouBRAVEHEART-11/19/1999
723 It is sooooo nice to see the institutional buying. thomsoninvest.net I'llJMarcus-11/18/1999
722 Marc, I'm an NTII bull and probably the most consistent rosy optimist postiDr. John M. de Castro-11/18/1999
721 Nice to be above $3 again. Agreed? :-) MarcJMarcus-11/18/1999
720 Do you think the anticipated good news is completely built into the current stoJMarcus-11/18/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News